OTC: HNSBF - Hansa Biopharma AB (publ)

六个月盈利: -3.41%
部门: Healthcare

促销时间表 Hansa Biopharma AB (publ)

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.

更多详情
The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.hansabiopharma.com
Цена ао 2.93
每日价格变化: 0% (2.83)
每周价格变化: 0% (2.83)
每月价格变化: -22.47% (3.65)
3个月内价格变化: -3.41% (2.93)
六个月内的价格变化: -3.41% (2.93)
每年价格变化: +25.39% (2.257)
3年内价格变化: -71.98% (10.1)
5年内价格变化: -90.78% (30.69)
10年价格变化: 0% (2.83)
年初以来价格变化: 0% (2.83)
所有参数

低估

姓名 意义 年级
P/S 8.84 1
P/BV -0.7013 0
P/E 0 0
EV/EBITDA -3.26 0
全部的: 3.5

效率

姓名 意义 年级
ROA, % -8.11 0
ROE, % 49.19 10
全部的: 3.33

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -11 10
全部的: 9.8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 320.69 10
盈利能力 Ebitda, % -78.54 0
盈利能力 EPS, % -81.15 0
全部的: 4
更多详情

机构 体积 分享, %
SPDR Portfolio Developed World ex-US ETF 115184 0.22
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF 30740 0.06
SPDR (R) Portfolio Europe ETF 611 0



导师 职称 支付 出生年份
Mr. Søren Tulstrup M.Sc President & CEO 16.12M 1965 (60 年)
Dr. Christian Kjellman Senior VP & COO N/A 1967 (58 年)
Dr. Hitto Kaufmann Ph.D. Chief Scientific Officer N/A 1971 (54 年)
Ms. Eva-Maria Joed Vice President of Finance & Administration N/A 1969 (56 年)
Mr. Klaus Sindahl VP & Head of Investor Relations N/A
Ms. Anne Säfström Lanner Senior VP & Chief Human Resources Officer N/A 1969 (56 年)
Mr. Emanuel Björne VP & Head of Business Development N/A 1973 (52 年)
Dr. Lena Winstedt Head of Science N/A 1969 (56 年)
Ms. Vincenza Nigro M.B.A. VP & Head of Medical Affairs N/A
Mr. C. Evan Ballantyne Chief Financial Officer N/A 1960 (65 年)

地址: Sweden, Lund, ScheelevAegen 22 - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.hansabiopharma.com